Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

AMIKACIN SULFATE INJECTION DIN 02486717

Status: Marketed
Holder: OMEGA LABORATORIES LIMITED
Molecule: AMIKACIN (AMIKACIN SULFATE)
Available to quote

Health Canada record

Active ingredient(s)AMIKACIN (AMIKACIN SULFATE) 250 MG
Dosage formSolution
RouteIntravenous; Intramuscular
SchedulePRESCRIPTION
ClassHuman
ATCJ01GB06 AMIKACIN
Original market date31-Jul-2019
Current status date31-Jul-2019
SourceHealth Canada DPD

Establishment licence of the holder

Omega Laboratories Ltd. (now Juno Pharma Canada Inc.) — licence 100277, not currently licensed, last inspection rating C (2025-05-20).

No Canadian shortage report is currently matched to this DIN.

Other Canadian products containing AMIKACIN (AMIKACIN SULFATE)

DINProductCompanyFormStrengthStatus
02173336AMIGLYDE-VZOETIS CANADA INCSolutionAMIKACIN (AMIKACIN SULFATE) 250 MGMarketed
02529459AMIKACIN SULFATE INJECTIONJAMP PHARMA CORPORATIONSolutionAMIKACIN (AMIKACIN SULFATE) 250 MGMarketed
02242971AMIKACIN SULFATE INJECTION USPSANDOZ CANADA INCORPORATEDLiquidAMIKACIN (AMIKACIN SULFATE) 250 MGMarketed
02481073AMIKACIN SULFATE INJECTION USPMARCAN PHARMACEUTICALS INCSolutionAMIKACIN (AMIKACIN SULFATE) 500 MGMarketed
02525909AMIKACIN SULFATE INJECTIONHIKMA CANADA LIMITEDSolutionAMIKACIN (AMIKACIN SULFATE) 250 MGCancelled Post Market
02539535AMIKACIN SULFATE INJECTIONJUNO PHARMACEUTICALS CORP.SolutionAMIKACIN (AMIKACIN SULFATE) 250 MGCancelled Pre Market
00397415AMIKINBRISTOL-MYERS SQUIBB CANADASolutionAMIKACIN (AMIKACIN SULFATE) 250 MGCancelled Post Market
02489147ERFA-AMIKACINSEARCHLIGHT PHARMA INCSolutionAMIKACIN (AMIKACIN SULFATE) 250 MGCancelled Post Market
02506599VPI-AMIKACINVPI PHARMACEUTICALS INCSolutionAMIKACIN (AMIKACIN SULFATE) 500 MGDormant

Notices of Compliance

NOCDateSubmissionReason
219762019-03-15Abbreviated New Drug Submission (ANDS)
Request a quote for AMIKACIN SULFATE INJECTION

How to read a Canadian DIN record